n=47 | |
Age, years | 68±12 |
BMI (kg/m2) | 22.9±4.2 |
NYHA class ≥3, n (%) | 22 (46.8) |
KCCQ score | 56.0±21.3 |
Male, n (%) | 16 (34.0) |
Syncope, n (%) | 12 (25.5) |
Hypertension, n (%) | 29 (61.7) |
Diabetes, n (%) | 2 (4.3) |
Dyslipidemia, n (%) | 27 (57.4) |
Smoking, n (%) | 4 (8.5) |
Stroke n (%) | 4 (8.5) |
Family history of sudden death, n (%) | 5 (10.6) |
Family history of HCM, n (%) | 7 (14.9) |
Atrial fibrillation, n (%) | 8 (17.0) |
COPD, n (%) | 2 (4.3) |
Coronary artery disease, n (%) | 4 (8.5) |
Peripheral artery disease, n (%) | 0 (0.0) |
Malignancy, n (%) | 8 (17.0) |
ICD/pacemaker implantation, n (%) | 6 (12.8) |
Medication, n (%) | |
Sodium channel blocker | 33 (70.2) |
Beta-blocker | 45 (95.7) |
Calcium channel blocker | 20 (42.6) |
Diuretics | 9 (19.1) |
Anticoagulation | 10 (21.3) |
Laboratory data | |
BNP (pg/mL) | 389.9 (156.0–802.4) |
Echocardiographic variables | |
LVEDD (mm) | 43.2±4.7 |
LVESD (mm) | 24.5±3.2 |
IVST (mm) | 20.9±3.0 |
LAD (mm) | 44.6±8.5 |
E/e’ (lateral) | 17.1±9.1 |
Moderate or severe MR, n (%) | 27 (57.0) |
Resting peak LVOT PG (mm Hg) | 97.6±37.1 |
Preprocedural resting peak LVOT PG (mm Hg) | 74.6±47.0 |
Data are expressed as mean±SD or median (quartiles), and number (%).
BMI, body mass index; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; IVST, intraventricular septal thickness; KCCQ, The Kansas City Cardiomyopathy Questionnaire; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEDP, left ventricular end-diastolic pressure.; LVESD, left ventricular end-systolic diameter; LVOT, left ventricular outflow tract; MR, mitral regurgitation; NYHA, New York Heart Association; PG, pressure gradient; PTSMA, percutaneous transluminal septal myocardial ablation.